Fighting Cancer: A Compelling Case for Artificial Intelligence in Genomics -- ADTmag

Fighting Cancer: A Compelling Case for Artificial Intelligence in Genomics

Artificial intelligence (AI) shows promise in its use as a part of routine clinical guidance. Pathologists leverage AI to provide expertly validated, up-to-date, comprehensive content to enable clinical reporting linking patients' sequencing results to potential therapeutic options using information extracted from medical literature and knowledge bases. This approach, which once required laborious literature searching by a team of bioinformaticians and oncologists, can now be completed in a fraction of the time.

Read this paper to learn how oncologists using IBM® Watson® for Genomics can quickly view insights from genomic data analysis which can be used to help them create personalized treatment plans for patients by:

Classifying cancer-causing mutations from a publicly available database
Mapping those mutations to therapeutic options using information extracted from the medical literature and knowledge bases
Helping save time

Download now!

Email Address

First Name

Last Name

Company

Job Title

Address

Country

City

State/Province

Postal Code

Phone

Phone ext

Which best describes your job title?

What is the total number of employees in your entire organization?

IBM may use my contact data to keep me informed of the products, services, and offerings.By EmailBy TelephoneBy Postal Mail

You can withdraw your marketing consent at any time by sending an email to [email protected]. Also you may unsubscribe from receiving marketing emails from IBM by clicking the unsubscribe link in each such email.

More information on IBM processing of your personal data can be found in the IBM Privacy Statement. By submitting this form, I acknowledge that I have read and understand the IBM Privacy Statement.

Your e-mail address is used to communicate with you about your registration, related products and services, and offers from select vendors. Refer to our Privacy Policy for additional information.